DelveInsight’s “Cervical Cancer- Market Insights, Epidemiology and Market Forecast-2023- EU5” Report provides marketed drugs information of Cervical Cancer. It has included historical and forecasted epidemiology and market size of the Cervical Cancer for Europe (Germany, Spain, France, Italy and United Kingdom) for 2013-2023. DelveInsight estimates that the therapeutic market size of Cervical Cancer in European (EU5) market is expected to grow at a Compound Annual Growth Rate of 0.019% and reach up to USD 109.8 million by 2023. The global market size of prophylaxis treatment for Cervical Cancer is expected to grow at a Compound Annual Growth Rate of 0.71% and reach up to USD 2210.9 Million by 2023.
Cervical Cancer needs to be focused more and more because it adversely affects younger women. It is the fourth most common cause of death among women. Cervical Cancer occurs due to the uncontrolled growth of healthy cells in cervix and forms cervical lesions. It spreads to other tissues such as vagina and uterus. Cervical Cancer is caused by inheritance of defects or mutation in genes. Cervical cancer is also caused due to the infection by the Human Papilloma Virus (HPV) which can infect cells on the surface of the skin and those lining the genitals, anus, mouth and throat, but not the blood or internal organs such as the heart or lungs.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
• Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details.
• The Report also covers the detailed global historical and forecasted epidemiological data for EU5 (France, Germany, Italy, Spain and UK) from 2013-2023.
• It also provides Market size of Cervical Cancer for EU5 (France, Germany, Italy, Spain and UK from 2013 and forecasted Market size to 2023.
• The report will help in developing business strategies by understanding the trends shaping and driving the EU5 (France, Germany, Italy, Spain and UK) market size of the Cervical Cancer
• Identifying patient populations in the EU5 (France, Germany, Italy, Spain and UK) Cervical Cancer market to improve product design, pricing, and launch plans.
• To understand the future market competition in EU5 (France, Germany, Italy, Spain and UK), Cervical Cancer therapeutics market, as well as prophylaxis and Insightful review of the key market drivers and barriers.
'
Report Introduction
Cervical Cancer Disease Overview
• Types of Cervical Cancer
• Staging of Cervical Cancer
• Pathophysiology
• Etiology
• Risk Factors of Cervical Cancer
Diagnosis of Cervical Cancer
Epidemiology and Patient Population of Cervical Cancer
United Kingdom (UK)
• Historical Incident Cases of Cervical Cancer in United Kingdom (UK) (2013-2015)
• Forecasted Incident Cases of Cervical Cancer in United Kingdom (UK) (2016-2023)
Germany (GE)
• Historical Incident Cases of Cervical Cancer in Germany (GE) (2013-2015)
• Forecasted Incident Cases of Cervical Cancer in Germany (GE) (2016-2023)
Italy (IT)
• Historical Incident Cases of Cervical Cancer in Italy (IT) (2013-2015)
• Forecasted Incident Cases of Cervical Cancer in Italy (IT) (2016-2023)
France (FR)
• Historical Incident Cases of Cervical Cancer in France (FR) (2013-2015)
• Forecasted Incident Cases of Cervical Cancer in France (FR) (2016-2023)
Spain (SP)
• Historical Incident Cases of Cervical Cancer in Spain (SP) (2013-2015)
• Forecasted Incident Cases of Cervical Cancer in Spain (SP) (2016-2023)
Treatment Landscape
Treatment Algorithm
Treatment by Stages
Cervical Cancer Treatment Regimens
Current Unmet Needs
Cervical Cancer Emerging therapies Market Size
a) Bevacizumab (Avastin)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
Avastin Historical Market Sales 2013-2015
Cost of therapy of Avastin
Cervical Cancer Prophylaxis Treatments
a) Cervarix (Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
Cervarix Historical Market Sales 2012-2015
Cost of therapy of Cervarix
b) Gardasil/ Gardasil 9
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
Gardasil Historical Market Sales 2012-2015
Cost of therapy of Gardasil
Pipeline Product (Phase III)
a) Z-100 (Ancer 20)
b) Axalimogene filolisbac or AXAL (ADXS11-001)
c) Gimeracil-Oteracil-Tegafur (S-1, TS-1)
Pipeline Product Analysis
Cervical Cancer Therapeutics Market in Europe5
• Historical market size of United Kingdom (UK) (2013-2015)
• Forecasted market size of United Kingdom (UK) (2016-2023)
• Historical market size of Germany (GE) (2013-2015)
• Forecasted market size of Germany (GE) (2016-2023)
• Historical market size of Italy (IT) (2013-2015)
• Forecasted market size of Italy (IT) (2016-2023)
• Historical market size of France (FR) (2013-2015)
• Forecasted market size of France (FR) (2016-2023)
• Historical market size of Spain (SP) (2013-2015)
• Forecasted market size of Spain (SP)(2016-2023)
Cervical Cancer Prophylaxis Treatment Global
• Historical Prophylaxis treatment market size (2013-2015)
• Forecasted Prophylaxistreatment market size (2016-2023)
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Table 1: Historical Incident Cases of Cervical Cancer in United Kingdom (UK) (2013-2015)
Table 2: Forecasted Incident Cases of Cervical Cancer in United Kingdom (UK) (2017-2023)
Table 3: Historical Incident Cases of Cervical Cancer in Germany (2013-2015)
Table 4: Forecasted Incident Cases of Cervical Cancer in Germany (2017-2023)
Table 5:Historical Incident Cases of Cervical Cancer in Italy (2013-2015)
Table 6: Forecasted Incident Cases of Cervical Cancer in Italy (2017-2023)
Table 7: Historical Incident Cases of Cervical Cancer in France (2013-2015)
Table 8: Forecasted Incident Cases of Cervical Cancer in France (2017-2023)
Table 9: Historical Incident Cases of Cervical Cancer in Spain (2013-2015)
Table 10: Forecasted Incident Cases of Cervical Cancer in Spain (2017-2023)
Table 11: Historical Cervical Cancer Therapeutics Market in United Kingdom (2013-2015)
Table 12: Forecasted Cervical Cancer Therapeutics Market in United Kingdom (2017-2023)
Table 13: Historical Cervical Cancer Therapeutics Market in Germany (2013-2015)
Table 14: Forecasted Cervical Cancer Therapeutics Market in Germany (2017-2023)
Table 15: Historical Cervical Cancer Therapeutics Market in Italy (2013-2015)
Table 16: Forecasted Cervical Cancer Therapeutics Market in Italy (2017-2023)
Table 17: Historical Cervical Cancer Therapeutics Market in France (2013-2015)
Table 18: Forecasted Cervical Cancer Therapeutics Market in France (2017-2023)
Table 19: Historical Cervical Cancer Therapeutics Market in Spain (2013-2015)
Table 20: Forecasted Cervical Cancer Therapeutics Market in Spain (2017-2023)
Table 21: Historical Cervical Cancer prophylaxis treatment global (2013-2015)
Table 21: Forecasted Cervical Cancer prophylaxis treatment global (2017-2023)
